Effect of early initiation of steroid-sparing drugs in patients with bullous pemphigoid

Introduction Bullous pemphigoid (BP) can be treated using systemic and topical glucocorticoids and/or other immunomodulatory agents. However, the long-term use of causes severe adverse side effects. This study was aimed at investigating whether early initiation corticosteroid-sparing therapy (CST) in BP patients results better outcomes than late or no CST. Method We retrospectively identified all referred to tertiary center, Department Dermatology Venerology, Aarhus University Hospital, Denmark, from 2015 2021. Patients’ demographics, comorbidities, treatment, remission BP, length admission, relapse, 1-year mortality were recorded. All who received CST dichotomised into two groups: initiated with <28 >28 days. The groups compared t-tests. Additionally, those alone. Our cohort that a previous (2006–2013) performed our department. In 2015, we revised treatment guidelines include Results On comparing group versus days, found significant differences complications between ( p = 0.63 =0.79, respectively). days had lower rate relapse < 0.05). data this study, conducted before guideline, reduced initial dose prednisolone admission time study. No Conclusion did not differ significantly subgroups group. implementation local guideline recommending